CRDL vs. DNA, VBV, CUS, FRX, AIM, APM, IPA, ITH, GPH, and GXE
Should you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Dalradian Resources (DNA), VBI Vaccines (VBV), Chemtrade Electrochem Inc, (CUS), Fennec Pharmaceuticals (FRX), Aimia (AIM), Andean Precious Metals (APM), ImmunoPrecise Antibodies (IPA), International Tower Hill Mines (ITH), Graphite One (GPH), and Gear Energy (GXE). These companies are all part of the "pharmaceutical products" industry.
Cardiol Therapeutics vs.
Dalradian Resources (TSE:DNA) and Cardiol Therapeutics (TSE:CRDL) are both small-cap basic materials companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
Dalradian Resources' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.
In the previous week, Cardiol Therapeutics had 2 more articles in the media than Dalradian Resources. MarketBeat recorded 2 mentions for Cardiol Therapeutics and 0 mentions for Dalradian Resources. Dalradian Resources' average media sentiment score of 0.00 beat Cardiol Therapeutics' score of -1.05 indicating that Dalradian Resources is being referred to more favorably in the media.
Given Dalradian Resources' higher possible upside, research analysts clearly believe Dalradian Resources is more favorable than Cardiol Therapeutics.
Dalradian Resources received 196 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. However, 69.23% of users gave Cardiol Therapeutics an outperform vote while only 66.78% of users gave Dalradian Resources an outperform vote.
Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Dalradian Resources, indicating that it is currently the more affordable of the two stocks.
11.4% of Cardiol Therapeutics shares are owned by institutional investors. 4.6% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Cardiol Therapeutics beats Dalradian Resources on 7 of the 13 factors compared between the two stocks.
Get Cardiol Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiol Therapeutics Competitors List
Related Companies and Tools
This page (TSE:CRDL) was last updated on 2/22/2025 by MarketBeat.com Staff
Free CRDL Stock Alerts